Isometronidazole
| Code | Size | Price |
|---|
| TAR-T21270-5mg | 5mg | £850.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Isometronidazole is a hypoxic cell sensitizer.
CAS:
705-19-1
Formula:
C6H9N3O3
Molecular Weight:
171.156
Purity:
0.98
SMILES:
Cc1nc(cn1CCO)[N+]([O-])=O
References
1. Schreiber A, Krause M, Zips D, D?rfler A, Richter K, Vettermann S, Petersen C, Beuthien-Baumann B, Th?mmler D, Baumann M. Effect of the hypoxic cell sensitizer isometronidazole on local control of two human squamous cell carcinomas after fractionated irradiation. Strahlenther Onkol. 2004 Jun;180(6):375-82. PubMed PMID: 15175873.
2. Hentschel M, Schmidt W. Pharmacokinetics of isometronidazole. Basic model and estimation of the kinetic parameters from experimental data. Pharmazie. 1992 Mar;47(3):221-4. PubMed PMID: 1615029.
3. Kob D, Lilienthal A, Bauhardt H, Merkle K, Schr?der E, Schr?der E, Hentschel M. [The radiation-sensitizing effect of isometronidazole following its intravesical application in bladder carcinoma. A clinical phase-II study]. Strahlenther Onkol. 1991 Sep;167(9):530-3. German. PubMed PMID: 1925936.
4. Zharkov VV, Merkle KKh, Gentshel M, Furmanchuk AV, Kurchin VP, Demidchik IuE, Moiseev PI. [The immediate results of the use of isometronidazole in the combination therapy of patients with lung cancer]. Med Radiol (Mosk). 1991;36(7):18-20. Russian. PubMed PMID: 1881282.